Cumberland Pharmaceuticals Inc. Appoints John Hamm as the Senior Director Finance & Accounting, Effective May 17, 2021
May 14, 2021 at 05:16 pm EDT
Share
On May 14, 2021, Cumberland Pharmaceuticals Inc. announced that its Board of Directors has appointed John Hamm as the Company’s Senior Director Finance & Accounting and Chief Financial Officer effective May 17, 2021. Mr. Hamm joined the Company on June 3, 2019 and assumed expanded responsibilities as the Director, Corporate Development on January 1, 2020. Mr. Hamm has over 25 years of finance and accounting experience, with a majority in the health care industry. He previously held the positions of Chief Operating Officer and Chief Financial Officer, Pharmacy at HealthSpring Inc., a managed care organization currently operating as Cigna-HealthSpring. Prior to that he was Vice President Finance at Emdeon Business Services. Emdeon Inc., a healthcare technology firm now operates as Change Healthcare Inc., a NASDAQ listed company with over $3 billion in annual revenue. Mr. Hamm, age 65 has a Bachelor of Science in Business Administration with a minor in Accounting from Wheeling University. He earned his Master’s in Business Administration with an emphasis in Accounting from the University of West Virginia. He is a Certified Management Accountant (CMA) and Certified Financial Manager (CFM). Mr. Hamm also assumes the role of Principal Financial Officer and Principal Accounting Officer of Cumberland. Michael Bonner, who has been serving as the Company’s Senior Director Finance & Accounting and Chief Financial Officer will transition out of that role effective May 17, 2021, as he pursues other interests outside of the Company. Mr. Bonner will continue to serve as a consultant to the Company. Mr. Hamm’s new employment agreement is included as an exhibit to this Form 8-K.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.